Companies › Rise Therapeutics
3 active drug programs in 3 registered trials: 3 Phase 1; Immunology, Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| R-2487 Probiotic | – | Phase 1 | Arthritis, Rheumatoid | Nov 2026 |
| R-5780 Probiotic (live microorganism) | – | Phase 1 | Solid Tumor, Adult | Mar 2029 |
| R-3750 Probiotic | – | Phase 1 | Ulcerative Colitis Chronic Mild | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05666960 | R-3750 | Phase 1 | Ulcerative Colitis Chronic Mild | Immunology | Jul 2026 |
| NCT05961592 | R-2487 | Phase 1 | Arthritis, Rheumatoid | Immunology | Nov 2026 |
| NCT06398418 | R-5780 | Phase 1 | Solid Tumor, Adult | Oncology | Mar 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.